Boston Partners Lowers Position in Sanofi (NYSE:SNY)
Boston Partners decreased its stake in shares of Sanofi (NYSE:SNY) by 4.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,161,184 shares of the company’s stock after selling 365,818 shares during the period. Boston Partners owned approximately 0.32% of Sanofi worth $391,002,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Guggenheim Capital LLC raised its stake in Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares in the last quarter. Gradient Investments LLC raised its stake in Sanofi by 15,470.7% in the first quarter. Gradient Investments LLC now owns 6,384 shares of the company’s stock valued at $289,000 after buying an additional 6,343 shares in the last quarter. Capstone Asset Management Co. raised its stake in Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock valued at $3,719,000 after buying an additional 4,635 shares in the last quarter. TNB Financial purchased a new stake in Sanofi during the first quarter valued at about $1,329,000. Finally, Atria Investments LLC raised its stake in Sanofi by 8.9% in the first quarter. Atria Investments LLC now owns 7,386 shares of the company’s stock valued at $334,000 after buying an additional 602 shares in the last quarter. 9.96% of the stock is currently owned by institutional investors and hedge funds.
Shares of Sanofi (NYSE:SNY) opened at 47.75 on Thursday. The firm has a market capitalization of $119.92 billion, a price-to-earnings ratio of 11.28 and a beta of 0.88. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24. The firm has a 50-day moving average price of $48.08 and a 200 day moving average price of $46.05.
Sanofi (NYSE:SNY) last posted its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. The business had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, analysts anticipate that Sanofi will post $3.26 EPS for the current fiscal year.
SNY has been the topic of several research reports. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, April 20th. Zacks Investment Research lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Berenberg Bank lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, BidaskClub lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Hold” and an average target price of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.